世界中医药

目的：探讨榄香烯乳剂联合TACE治疗中晚期肝癌的疗效与安全性。方法：选取2015年2月至2017年2月在上海中医药大学附属上海市中医医院肿瘤科收治的中晚期肝癌患者80例，将患者随机分为观察组（n=40）和对照组（n=40）。对照组给予TACE治疗，观察组在对照组的基础上联合榄香烯乳剂治疗。观察2组患者中医证侯疗效、肝功能、生命质量以及不良反应发生率。结果：观察组中医证侯改善率（8000%）明显大于对照组（4750%）（P<005）；观察组在改善患者ALT、AST、GGT、TBIL方面均优对照组（P<005）；观察组治疗后KPS评分（8649±1203）明显大于对照组（7414±1367）（t=4289，P<005）；2组不良反应情况比较差异无统计学意义（P<005）。结论：榄香烯乳剂联合TACE治疗中晚期肝癌患者能明显改善患者中医临床症状、肝功能以及生命质量，而不良反应均可缓解，值得临床推广。

English Summary:

To investigate the curative effect and safety of the elemenum emulsion combined with TACE treatment in treating the middle-late stage of liver cancer. Methods:A total of 80 cases of middle-late liver oncology who were treated in Shanghai university of traditional Chinese medicine affiliated hospital of traditional Chinese medicine from February 2015 to February 2015 were selected and randomly divided into observation group (n＝40) and the control group (n＝40). The control group was given conventional treatment, and the observation group was given joint elemenum emulsion treatment on the basis of control group. TCM syndrome curative effect, liver function, quality of life and the incidence of adverse reactions of two groups were observed. Results:The improvement rate of TCM syndrome in observation group (8000%) was significantly greater than the control group (4750%) (P<005); The improvement of ALT, AST, GGT, TBIL in observation group was better than control group (P<005); after treatment, KPS score (8649±1203) of the observation group was significantly greater than the control group (7414±1367) (t=4289, P<005); The adverse reaction conditions were similar between the two groups, without statistical significance (P<005). Conclusion:Elemenum emulsion combined with TACE in the treatment of patients with middle-late stage of liver cancer can significantly improve the clinical symptoms, liver function and quality of life, and adverse reactions can alleviate, which is worthy of clinical promotion.

查看全文查看/发表评论下载PDF阅读器